Cutanos

Delivery of antigen to specialised immune cells, called dendritic cells (DCs), is a promising approach to realise innovative vaccines, as well as immunotherapies against cancer and auto immune diseases. However, there are different subsets of DCs which can process the delivered antigen in different, sometimes adverse ways. This unspecific uptake can cause unwanted side effects, unnecessary off-target distribution and, as a consequence, reduced efficacy. Cutanos company to apply LC-TDS to provide a highly modular antigen delivery platform that only targets one specific type of DCs - Langerhans cells. Thus, the drug load will be reduced, the efficiency will be increased and the antigen delivery control will be unprecedented. Additionally, the LC-TDS can be applied by minimal-invasive techniques, allowing for painless, save and patient convenient administration.